LOGIN

[theme-my-login]

Hi! Some company words

Fusce elementum tristique leo, nec scelerisque lacus eleifend vel. Mauris vehicula urna sed quam vehicula, ac porta arcu molestie. Etiam in lectus lectus. Sed eget nibh a urna accumsan convallis venenatis ac massa. Donec tincidunt mattis pretium. Proin ac blandit ligula, et mattis diam. Nulla et mattis arcu, ut ullamcorper dolor. Donec porta sem nisi, eu scelerisque elit semper ac. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Duis malesuada ligula eget odio vulputate, quis imperdiet tortor pharetra. Aenean auctor lobortis ligula sit amet iaculis. Aenean accumsan nibh porttitor malesuada pellentesque. Nam justo urna, tempus a rhoncus nec, porta et lorem. Duis vel condimentum eros, sit amet tempus odio. Duis volutpat iaculis enim, eget malesuada urna fringilla eu. Praesent vel aliquam lorem.

Our contacts

Fusce dapibus, tellus commodo, tortor mauris condimentum utellus fermentum, porta sem.

Phone:    (212) 555 55 00 or (212) 555 55 00

Adress:    Company LTD Street nr 100, 4536534, Chicago, US

sales@yourwebsite.com

Innovative, cost-effective, "best in class" solutions to pressing problems in the global medical industry.

CITOFEM PLUS = Citofem and Viro-safe. For use in the United States and its Territories.

For information on Citofem Plus presentations for international use click below

CITOFEM PLUS = Citofem® + Viro-safe®

Citofem® + Viro-safe® components provide the most complete perspective on diagnosis with critical adjunct diagnostic information.

Citofem® and Viro-Safe® components are designed to work optimally together to provide the most complete information for physicians and their patients.  

 In standard in vitro clinical practice, cytology is the first analytical step.  A sample of cells is taken from a patient and analyzed using Citofem®’s liquid cytology system, following Citofem®’s instructions and the accepted cytology protocols (bucal, penile, vaginal, anal, cervical, pleural, etc) for determination of abnormal cells.  

In case of an inconclusive cytology result, the identification of a dysplasia, or a physician’s decision to do so, confirmatory testing with Viro-Safe® can be conducted in the same laboratory, with the same equipment, and using the same patient sample to detect the presence of the L1 capsid protein of HPV high risk strains and their current activity.  Follow-up testing with Viro-safe® can be conducted up to 90 days later from the original Citofem® patient sample.

CITOFEM PLUS® components versus Competitors

1) Highest quality results

2) When used sequentially (Citofem®, with VIRO-safe® components confirmatory test)

Includes much more information than other test/follow-up combinations on the market.

3) Simple and fast

Perfect complementarity with Citofem (results in hours)

4) Allows any cytology or pathology lab to provide highest quality tests on market with existing lab equipment and personnel

5) No special equipment required to process

6) No need for patient to return to lab, different lab or physician´s office for complete information

7) The compatible components provide better cell and viral load capture

8) All at a fraction of the price of current test/follow up combinations

Citofem® plus VIRO-Safe®Cytology plus PCR
Simple inmunocytochemistry techniqueMore complex molecular biology technique using DNA extraction
Identifies presence of active infection through L1 capsid protein of high risk strainsDetermines presence of viral DNA giving inconclusive and alarming information to patient (nearly 100% of women under 30 expected to test positive)
Diagnostic and activity informationIdentifies only presence of virus
Simple, quick process with results in two hoursMore complex, multi day, multi-step process
Requires no additional specialized equipmentRequires PCR processor (US$5,000 to US$ 200,000)

Viro-safe confirmation also shows viral activity

Citofem® components, like all high quality liquid cytology tests, provide critical information to the patient’s physician allowing a diagnosis based on the presence or absence of cancerous tissues or precancerous lesions.  Because Viro-Safe® components determine the presence of the L1 capsid protein of the HPV high risk strains, rather than the presence of virus DNA (as in all molecular biology-based tests),  Viro-Safe® components provide accurate information on the activity of the virus (e.g. presence of L1 capsid indicates the presence of  the virus in active state). This information, when confirming Citofem®’s results, provides a physician with very complete picture to present the patient’s diagnosis including valuable adjunctive diagnostic information.

Presentation

  • Citofem and Viro-safe are sold as components.
  • 500 Citofem tests are sold with 50 Viro-safe tests
  • Viro-safe is also sold as a replacement components